Sinués Blanca, Fanlo Ana, Bernal María Luisa, Mayayo Esteban, Soriano María Antonia, Martínez-Ballarin Enrique
Department of Pharmacology, Medical School, University of Zaragoza, Zaragoza, Spain.
Ther Drug Monit. 2002 Dec;24(6):715-21. doi: 10.1097/00007691-200212000-00006.
Five established metabolite ratios (MRs) to measure P450 CYP1A2 activity--MR1 (17X + 17U)/137X, MR2 (AFMU + 1X + 1U)/17U, MR3 (17X/137X), MR4 (AFMU + 1X + 1U + 17X + 17U)/137X, and MR5 (AFMU + 1X + 1U)/17X--were calculated in urine 4-5 hours after caffeine intake. First, to assess the potential of omeprazole to induce CYP1A2 activity, a caffeine test was performed in 27 subjects on two occasions: before and after 14 days on omeprazole (20 mg/day). Samples of urine were analyzed by high-performance liquid chromatography (HPLC) to quantify caffeine and metabolites used to calculate the different caffeine MRs. MR1, MR3, and MR4 were enhanced after treatment; the percentage of change was inversely associated with that of the urine flow, with r values of -0.48, -0.49, and -0.47, respectively. However, MR2 or MR5 were not modified. To determine the reason for these contradictory results, the authors analyzed data of metabolites, ratios, and their components (numerators and denominators) from 152 subjects (who underwent one caffeine test) and their relationship with the urinary flow. Caffeine concentration in urine was the only compound nondependent on the urine flow. Consistently, ratios containing caffeine (MR1, MR3, and MR4) were highly influenced by the rate of urine excretion, since the flow dependence of their numerators is not canceled out by that of caffeine in their denominators. The dependency of the caffeine excretion on renal factors may explain the opposite results found with the different ratios in the aforementioned prospective study of drug interaction, the absence of closer correlations of the five MRs to each other, the discrepancies about the type of frequency distribution of the different MRs (either normal or multimodal), and the higher sensitivity of MR2 to detect gender differences in CYP1A2 activity found in this study. In summary, the data clearly emphasize the need for a strict control of the liquid intake to avoid high urine flows when MRs containing caffeine are used to assess CYP1A2 activity, especially in studies of drug interactions.
计算了用于测量细胞色素P450 CYP1A2活性的五个既定代谢物比率(MRs)——MR1(17X + 17U)/137X、MR2(AFMU + 1X + 1U)/17U、MR3(17X/137X)、MR4(AFMU + 1X + 1U + 17X + 17U)/137X和MR5(AFMU + 1X + 1U)/17X,在摄入咖啡因后4 - 5小时的尿液中进行计算。首先,为了评估奥美拉唑诱导CYP1A2活性的潜力,对27名受试者进行了两次咖啡因测试:一次在服用奥美拉唑(20毫克/天)14天之前,另一次在之后。通过高效液相色谱法(HPLC)分析尿液样本,以定量用于计算不同咖啡因MRs的咖啡因和代谢物。治疗后MR1、MR3和MR4升高;变化百分比与尿流呈负相关,r值分别为 -0.48、-0.49和 -0.47。然而,MR2或MR5未改变。为了确定这些矛盾结果的原因,作者分析了152名受试者(进行了一次咖啡因测试)的代谢物、比率及其组成部分(分子和分母)的数据,以及它们与尿流的关系。尿液中的咖啡因浓度是唯一不依赖于尿流的化合物。一致地,含有咖啡因的比率(MR1、MR3和MR4)受尿液排泄率的高度影响,因为它们分子对尿流的依赖性未被分母中咖啡因的依赖性抵消。咖啡因排泄对肾脏因素的依赖性可能解释了在上述药物相互作用的前瞻性研究中不同比率出现的相反结果、五个MRs之间缺乏更紧密的相关性、不同MRs频率分布类型(正态或多峰)的差异,以及本研究中发现的MR2在检测CYP1A2活性性别差异方面更高的敏感性。总之,数据清楚地强调了在使用含有咖啡因的MRs评估CYP1A2活性时,尤其是在药物相互作用研究中,需要严格控制液体摄入量以避免高尿流。